Table 4. Comparison of WHO-5 score changes from baseline at the end of the two-week intervention in the aroma- and placebo-seal groups.
| Adjusted Means (95% CI) | Differences of LSMD | p-value | Effect size | ||
|---|---|---|---|---|---|
| Aroma-seal use group (n = 31) | Placebo-seal use group (n = 30) | ||||
| Total Score | 3.32 (2.15 to 4.49) | 1.67 (0.48 to 2.85) | 1.66 (−0.01 to 3.33) | 0.05 | 0.51 |
| W1 | 0.42 (0.12 to 0.71) | 0.20 (−0.10 to 0.50) | 0.22 (−0.20 to 0.64) | 0.3 | 0.27 |
| W2 | 0.80 (0.56 to 1.05) | 0.37 (0.12 to 0.62) | 0.44 (0.09 to 0.79) | 0.02 | 0.64 |
| W3 | 0.60 (0.27 to 0.93) | 0.28 (−0.06 to 0.62) | 0.32 (−0.16 to 0.79) | 0.19 | 0.34 |
| W4 | 0.92 (0.52 to 1.32) | 0.55 (0.15 to 0.95) | 0.37 (−0.19 to 0.94) | 0.19 | 0.34 |
| W5 | 0.60 (0.28 to 0.92) | 0.25 (−0.08 to 0.58) | 0.35 (−0.11 to 0.81) | 0.13 | 0.40 |
LSMD, least squares mean difference